Zavala VJA, Rojas PE, López MC, Cruz GH, Espinosa del Río ER

Language: Spanish
References: 16
Page: 109-113
PDF size: 117.06 Kb.

ABSTRACT

Upon approval by the Ethics Committee we conducted a longitudinal, prospective and comparative study to evaluate the postoperative preventive analgesic action of parecoxib. Material and methods: Prior to surgery, forty knee surgery patients (ASA I/II) received regional anesthesia. Patients were divided in two groups: group M (GM) (n = 20) received 30 mg/kg/IV metamizol; group P (GP) (n = 20) received 40 mg/IV parecoxib. Both drugs were administered as a single dose after neuroaxial block. Results: Parecoxib showed greater management of post-operative pain and for 30 minutes after the surgery. Greater analgesic efficacy was shown with metamizol after the first four hours of surgery. Conclusions: The effects of parecoxib and metamizol for analgesic prevention were similar. Analgesia provided by parecoxib by better only or the firs 60 minutes of the post-operative period. The use of either parecoxib or metamizol for analgesic prevention achieve only moderate relief, therefore require salvage with opiates such as nalbuphine.

REFERENCES

1. Rowbotham DJ. Pain management. Anaesthesia 2003; 58: 1196-1199.

2. Joshi GP, White PF. Management of acute and postoperative pain. Cur Opin Anaesthesiol 2001; 14: 417-421.

3. Ibrahim AE, Feldman JB, Karim A, Kharasch ED. Simultaneous assessment of drug interactions with low- and high-extraction opioids: Application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanyl. Anesthesiology 2003; 98: 853-861.

4. Gibbs BF, Boehncke WH. Effects of rofecoxib, celecoxib, and parecoxib on anti-IgE-induced histamine release from human skin mast cells and basophils. Allergy 2003; 58: 1075-1076.

5. Cheer SM, Goa KL. Parecoxib (parecoxib sodium). Drugs 2001; 61: 1133-1141.

6. Gajraj NM. FRCA cyclooxygenase-2 inhibitors. Anesth Analg 2003; 96: 1720-1738.

7. Karim A, Laurent A, Qian J, Kuss M, Hubbard R. Single dose tolerability and pharmacokinetics of parecoxib sodium, a cox-2 specific inhibitor, following intravenous administration. ASA Annual Meeting Abstracts. Local Anesthesia Pain 2000; 93: 945.

8. Samad T, Abdi S. Cyclooxygenase-2 and antagonists in pain management. Cur Opin Anaesthesiol 2001; 14: 527-532.

9. Stephens J, Laskin B, Pashos C, Pena B, Wong J. The burden of acute postoperative pain and the potential role of the COX-2-specific inhibitors. Rheumatology 2003; S42: 40-52.

10. Bulut D, Liaghat S, Hanefeld Ch, Koll R, Miebach T, Mugge A. Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension. J Hypert 2003; 21: 1663-1667.

11. Stiller CO, Hjemdahl P. Endothelial COX-2 inhibition: Possible relevance for hypertension and cardiovascular risk? J Hypert 2003; 21: 1615-1618.

12. Meagher EA. Balancing gastroprotection and cardioprotection with selective cyclo-oxygenase-2 inhibitors: Clinical implications. Drug Safety 2003; 26: 913-924.

13. Wender RH, Desai PM, Snabes MC, Talwalker SC, Kuss ME, Hubbard RC. Parecoxib sodium demonstrates opioid sparing effects in post-laparotomy surgical patients. Fertility Sterility. 2001; 76: 218-219.

14. Hubbard RC, Naumann TM, Traylor L, Dhadda S. Parecoxib sodium has opioid-sparing effects in patients undergoing total knee arthroplasty under spinal anaesthesia. Br J Anaesth 2003; 90: 166-172.

15. Hubbard RC, Stulberg BN, Torri SM, Talwalker S, Kuss ME. The COX-2 specific inhibitor parecoxib sodium is effective in treating post-operative pain in total hip arthroplasty patients. ASA Annual Meeting Abstracts. Local Anesthesia Pain 2001; 95: 807.

16. Malan T, Philip Jr, Marsh G, Hakki SI, Grossman EB, Traylor L, Hubbard RC. Parecoxib sodium, a parenteral cyclooxygenase 2 selective inhibitor, improves morphine analgesia and is opioid-sparing following total hip arthroplasty. Anesthesiology 2003; 98: 950-956.